Featuring an interview with Dr Ezra Cohen, including the following topics: Spectrum of targetable mutations in thyroid cancer and impact on treatment selection (0:00) Comparative efficacy of TRK inhibitors in patients with thyroid cancer, including those with CNS disease (6:06) Current and emerging roles of immunotherapy alone and in combination with tyrosine kinase inhibitors for patients with head and neck cancer (10:17) Predicting clinical response to immunotherapy for patients with head and neck cancers (19:47) Role of dose reduction in managing toxicities associated with immunotherapy and targeted agents (26:01) Current and potential roles for cell-free DNA testing and minimal residual disease assessment in the management of head and neck cancer (32:08) Recently reported efficacy data with avasopasem in the treatment of radiation-induced oral mucositis (35:27) Factors affecting response to immunotherapy (42:07) CME information and select publications

Ver todos los episodios